Abstract Library

#4601 Pembrolizumab combined with cisplatin or carboplatin and etoposide in treatment naïve advanced Merkel cell carcinoma (MCC): The phase II PANDORA Trial

Introduction: MCC is a rare and aggressive skin neuroendocrine tumour with high metastatic potential and mortality. Therapeutic options in metastatic/unresectable MCC are based on immunotherapy or platinum-based chemotherapy. However, a subgroup of patients (pts) has primary immunoresistance disease, so it would be important discover active upfront combinations. PANDORA trial [NCT 06086288] is an open-label, multicentre, single-arm phase II trial evaluating the activity and safety of pembrolizumab (PEM) combined with platinum-based chemotherapy as 1st line treatment in pts with metastatic, unresectable or recurrence MCC. Supported in part by a research grant from Investigator-Initiated Studies Program of MSD.

Conference:

Presenting Author: Oldani S

Authors: Oldani S, Morano F, Cingarlini S, Di Giacomo A, Borghesani M,

Keywords: Pembrolizumab, clinical trial, Merkel cell carcinoma, chemio-immunotherapy,

#4388 Pancreatic neuroendocrine tumours (pNET) and MUTYH germline (GPV) and somatic (SPV) pathogenic variants: A multinational study

Introduction: GPV and SPV in MUTYH are rare in pNET patients (pts).

Conference:

Presenting Author: Riechelmann R

Authors: Riechelmann R, Torrezan G, Cingarlini S, Raj N, Bergsland E,

Keywords: pancreatic neuroendocrine tumour, MUTYH, germline, pathogenic variants, mutations,

#3860 NGS data collection in high-grade (HG) pancreatic NENs at University Hospital of Verona

Introduction: Molecular data for G3 pancreatic neuroendocrine neoplasms (pNEN) are limited. G3 category includes well-differentiated NET G3 and NEC. The biology and clinical behaviour of NET G3 are different from NEC.

Conference:

Presenting Author: Rossi A

Authors: Rossi A, Cingarlini S, Borghesani M, Moscarda V, Torresan I,

Keywords: NGS, pNEN, G3, precision medicine,

#2253 The Evolution of Surgical Strategies for Pancreatic Neuroendocrine Tumors (Pan-NENs): Time-Trend and Outcome Analysis from 587 Consecutive Resections at a High-Volume Institution

Introduction: Reflecting their rarity and heterogeneity, Pan-NENs represent a clinical dilemma and there is a scarcity of data regarding their long-term follow-up after resection.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Marchegiani G

Authors: Marchegiani G, Landoni L, Pollini T, Miotto M, Cingarlini S,

Keywords: Pancreas, Pan-NENs, Surgery, NET,

#2249 Pasireotide as a Possible Tool for the Control of Refractory Hyperinsulinemic Hypoglycemia from Malignant Insulinoma

Introduction: The control of hypoglycemic hyperinsulinemic syndrome from malignant insulinoma is challenging because it is often refractory to diazoxide and somatostatin analogues (SA). Everolimus can have side effects that can limit its use. Pasireotide, a multi-receptor-targeted SA with a high binding affinity to SSTR1 and SSTR5, exhibits a strong inhibitory effect of insulin secretion.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Davi' M

Authors: Zambon G, Cosaro E, Cingarlini S, Trombetta M, Landoni L,

Keywords: pasireotide, malignant insulinoma, hypoglycemia,